Daphne T Hsu, Victor Zak, Lynn Mahony, Lynn A Sleeper, Andrew M Atz, Jami C Levine, Piers C Barker, Chitra Ravishankar, Brian W McCrindle, Richard V Williams, Karen Altmann, Nancy S Ghanayem, Renee Margossian, Wendy K Chung, William L Border, Gail D Pearson, Mario P Stylianou, Seema Mital
BACKGROUND: Angiotensin-converting enzyme inhibitor therapy improves clinical outcome and ventricular function in adults with heart failure. Infants with single-ventricle physiology have poor growth and are at risk for abnormalities in ventricular systolic and diastolic function. The ability of angiotensin-converting enzyme inhibitor therapy to preserve ventricular function and improve somatic growth and outcomes in these infants is unknown. METHODS AND RESULTS: The Pediatric Heart Network conducted a double-blind trial involving 230 infants with single-ventricle physiology randomized to receive enalapril (target dose 0...
July 27, 2010: Circulation